According to the summary conclusions in the paper Ernie posted:
"This analysis underlines the usefulness of rapid DOAC measurement and the value of PopPK models to estimate concentrations at trough in a context where the post-intake delay is unmanageable."
This struck me as being somewhat of a promotion of an assay in development. This coupled with the need to "estimate concentrations at trough" implies a requirement to know when the patient last ingested their prescribed DOAC, followed by multiple plasma samplings to determine when the DOAC will be at minimum levels - meanwhile, the patient bleeds.
I agree with docoftheforce regarding the significance of the in-vitro data recently reported as being potentially practice-changing.